Effects of the Multi‐kinase Inhibitor Midostaurin in Combination With Chemotherapy in Models of Acute Myeloid Leukaemia

Journal of Cellular and Molecular Medicine - United Kingdom
doi 10.1111/jcmm.14927
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Combination Treatment of an IDH1 Inhibitor With Chemotherapy in IDH1 Mutant Acute Myeloid Leukemia

Annals of Hematology
MedicineHematology
2020English

Stochastic Modelling of Tyrosine Kinase Inhibitor Rotation Therapy in Chronic Myeloid Leukaemia

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

A Novel Combination Therapy Approach for the Treatment of Acute Myeloid Leukemia: The Multi-Kinase Inhibitor Sorafenib and the HDM2 Inhibitor Nutlin-3

Haematologica
Hematology
2012English

Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Cognitive Dysfunction After Withdrawal of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

American Journal of Hematology
Hematology
2016English

Prognosis in Acute Myeloid Leukaemia.

BMJ
1981English

Razoxane in Treatment of Acute Myeloid Leukaemia.

BMJ
1978English

Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor

Cureus
2019English

Frequent Loss of RAF Kinase Inhibitor Protein Expression in Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy